What question did this study set out to answer?

This analysis aims to evaluate the cost-effectiveness of the Aptima test relative to the PCR DNA test for HPV screening.

April 28, 2026Open Access

Cost-Effectiveness Analysis of the Messenger RNA Test (Aptima®) Compared With the Polymerase Chain Reaction DNA Test for Human Papillomavirus Screening From the Colombian Perspective

Key Points

This analysis aims to evaluate the cost-effectiveness of the Aptima test relative to the PCR DNA test for HPV screening.
Comparative cost-effectiveness analysis based on screening strategies
Focus on women over 30 years old
Contextual analysis within the Colombian health system
Aptima test demonstrates increased cost-effectiveness compared to PCR, improving screening efficiency
Implementation of the Aptima test can optimize resource allocation in HPV prevention
Overall reduction in long-term healthcare costs associated with HPV-related conditions

Abstract

The Aptima test represents a cost-effective strategy for screening HPV infection in women over 30 years of age, compared with the polymerase chain reaction DNA test, within the context of the Colombian health system.

Bookmark

View Full Paper